Cargando…

Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy

OBJECTIVE: To identify and characterize patients with autoantibodies against different neurofascin (NF) isoforms. METHODS: Screening of a large cohort of patient sera for anti-NF autoantibodies by ELISA and further characterization by cell-based assays, epitope mapping, and complement binding assays...

Descripción completa

Detalles Bibliográficos
Autores principales: Stengel, Helena, Vural, Atay, Brunder, Anna-Michelle, Heinius, Annika, Appeltshauser, Luise, Fiebig, Bianca, Giese, Florian, Dresel, Christian, Papagianni, Aikaterini, Birklein, Frank, Weis, Joachim, Huchtemann, Tessa, Schmidt, Christian, Körtvelyessy, Peter, Villmann, Carmen, Meinl, Edgar, Sommer, Claudia, Leypoldt, Frank, Doppler, Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705632/
https://www.ncbi.nlm.nih.gov/pubmed/31454780
http://dx.doi.org/10.1212/NXI.0000000000000603
Descripción
Sumario:OBJECTIVE: To identify and characterize patients with autoantibodies against different neurofascin (NF) isoforms. METHODS: Screening of a large cohort of patient sera for anti-NF autoantibodies by ELISA and further characterization by cell-based assays, epitope mapping, and complement binding assays. RESULTS: Two different clinical phenotypes became apparent in this study: The well-known clinical picture of subacute-onset severe sensorimotor neuropathy with tremor that is known to be associated with IgG4 autoantibodies against the paranodal isoform NF-155 was found in 2 patients. The second phenotype with a dramatic course of disease with tetraplegia and almost locked-in syndrome was associated with IgG3 autoantibodies against nodal and paranodal isoforms of NF in 3 patients. The epitope against which these autoantibodies were directed in this second phenotype was the common Ig domain found in all 3 NF isoforms. In contrast, anti–NF-155 IgG4 were directed against the NF-155–specific Fn3Fn4 domain. The description of a second phenotype of anti–NF-associated neuropathy is in line with some case reports of similar patients that were published in the last year. CONCLUSIONS: Our results indicate that anti–pan-NF-associated neuropathy differs from anti–NF-155-associated neuropathy, and epitope and subclass play a major role in the pathogenesis and severity of anti–NF-associated neuropathy and should be determined to correctly classify patients, also in respect to possible differences in therapeutic response.